The Restorative webinar got me thinking about the TGA engagement and notably that it wasn't mentioned as an upcoming catalyst in the quarterly update. I am wondering if there is no urgency from LTR on this, as a result of them having contributed to the costs of Restorative's Online Tele Health Platform. Once the product is TGA approved it does opens it up to being prescribed by any doctor, so Restorative lose the monopoly that currently exists with the product under the special access scheme. I know the FDA approval is the key driver but just a thought and nothing more.
Interesting though the video / story about the chap who had prostate cancer and had tried various different ED treatments after and yet the only product that enable him to achieve an erection was Spontan. This is the second person I have heard of who also had ED issues from prostate cancer, and the only ED treatment that enabled him to get back in the saddle, so to speak of, was Spontan as well.
LTP Price at posting:
37.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)